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To the Editor,
There is no doubt that during performance 
basophil activation test (BAT) many factors 
influencing the procedure must be taken un-
der consideration. These include many issues 
connected with pre- laboratory stage, laboratory 
procedure (performance of basophil activation 
test) and evaluation or interpretation of the 
results. Many concerns raised by the Author of 
the comments [1] are connected to phenotyping 
protocol. In presented case BAT was performed 
with commercial available kit with respect to 
the instruction (FlowCAST highsens Bühlmann 
Laboratories, Switzerland). An allergen used in 
the assay (acetylsalicylic acid-lysine) was also 
from commercial source. Flow cytometer used 
to analysis was Becton Dickinson, FACSCanto 
II. In order to capture basophils from whole 
blood sample identification protocol contained 
as a selection marker for basophils monoclo-
nal antibody anti-CCR3-PE (eotoxin receptor, 
CD193). Additionally, due to the fact that it does 
exist also on eosinophils, therefore the separa-
tion by side scatter, to distinguish between this 
two cell populations, was performed. Basophils 
were gathered in a low side-scatter cells region. 
Two positive controls were performed — fMLP 
and antibody to FceRI. The basophil activation 
was assessed by anti-CD63/CD203c — PE-
DY647. Spontaneously activated basophils were 
estimated on 2−2,5% (patients background 
sample). CCR3 as a selection marker is thought 
to be expressed on basophils surface in a high 
level [2].
In the gating protocol we do not use IL-3 to 
enhance the basophils responsiveness. The analy-
ses were based on the cut off values suggested by 
the test’s producer. We are preparing our own, 
detailed analyses of patients population diagno-
sed to NSAIDS hypersensitivity containing com-
parison of medical history, laboratory diagnostic 
method and in vivo challenge test. 
Regarding to nomenclature non releaser and 
nonresponder subject — these two name can be 
founded in articles [3, 4].
The nonsteroidal anti-inflammatory drugs 
hypersensitivity reactions present a wide range 
of clinical symptoms, one of their manifestation 
is anaphylaxis. In presented case of a patient 
who has undergone anaphylactic shock other 
possible causes of reaction were eliminated. 
Detailed medical history did not reveal any 
previous reaction after contact with supposed 
allergens, which could help in carrying out of 
the diagnosis. Furthermore, patient did not suffer 
from any comorbidities — i.e. asthma, chronic 
sinusitis with nasal polyps or chronic pruritus 
(AERD, NIUA), which may enhance the proba-
bility of NSAIDs hypersensitivity. According to 
the guidelines [5] the oral challenge test should 
be performed to confirm the diagnosis. However, 
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in the case of severe anaphylaxis provocation test 
is not recommended. 
Many aspects, that have to be taken in acco-
unt in performance and assessment of basophil 
activation test, raise many doubts and questions 
regarding this diagnostic assay. It is worth noting 
that multiple protocols use in clinical and scien-
tific work confirm development of this branch 
of diagnostic methods and the need of searching 
new suitable protocol elements. There is no 
one „gold standard” in performing procedure, 
that preclude in many cases comparison of BAT 
results. Mentioned by the Author “Consensus 
Panel” may suggest some standard leading to 
guidelines. Open discussion on the journal pa-
ges and BAT concerned meetings like EuroBat 
that held in December 2014 are good examples 
of this process.
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